Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» JNJ-6372
JNJ-6372
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
BioSpace
Janssen
JNJ
FDA
JNJ-6372
breakthrough therapy
metastatic non-small cell lung cancer
Flag link:
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Pharmaceutical Business Review
Janssen
JNJ
FDA
JNJ-6372
metastatic non-small cell lung cancer
Flag link:
